Evidence map›Paper›PMID 26223303›Full record

ArticleScience translational medicine2015

Quality and quantity of TFH cells are critical for broad antibody development in SHIVAD8 infection.

Takuya Yamamoto, Rebecca M Lynch, Rajeev Gautam, Rodrigo Matus-Nicodemos, Stephen D Schmidt, Kristin L Boswell, Sam Darko, Patrick Wong, Zizhang Sheng, Constantinos Petrovas and 9 more

Abstract read
PubMed Publisher
In one paragraph

Article in Science translational medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers.

0numbers the graph read from it
0cells of the map it votes in
93citing papers in PubMed
9.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

93 citing papers in PubMed, 119 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. HIV-1-Infected CD4Journal of immunology (Baltimore, Md. : 1950) · 2022
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Interleukin-21 in Viral Infections.International journal of molecular sciences · 2021
    Review
  19. Article
  20. Article

33 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 3 institutions in 1 country.

Takuya YamamotoImmunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD 20892, USA.
Rebecca M LynchHumoral Immunology Section, Vaccine Research Center, NIAID, NIH, Bethesda, MD 20892, USA.
Rajeev GautamLaboratory of Molecular Microbiology, NIAID, NIH, Bethesda, MD 20892, USA.
Rodrigo Matus-NicodemosImmunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD 20892, USA.
Stephen D SchmidtHumoral Immunology Section, Vaccine Research Center, NIAID, NIH, Bethesda, MD 20892, USA.
Kristin L BoswellImmunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD 20892, USA.
Sam DarkoHuman Immunology Section, Vaccine Research Center, NIAID, NIH, Bethesda, MD 20892, USA.
Patrick WongHumoral Immunology Section, Vaccine Research Center, NIAID, NIH, Bethesda, MD 20892, USA.
Zizhang ShengDepartment of Biochemistry and Molecular Biophysics, Columbia University, New York, NY 10032, USA.
Constantinos PetrovasImmunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD 20892, USA.
Adrian B McDermottImmunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD 20892, USA.
Robert A SederCellular Immunology Section, Vaccine Research Center, NIAID, NIH, Bethesda, MD 20892, USA.
Brandon F KeeleAIDS and Cancer Virus Program, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
Lawrence ShapiroDepartment of Biochemistry and Molecular Biophysics, Columbia University, New York, NY 10032, USA.
Daniel C DouekHuman Immunology Section, Vaccine Research Center, NIAID, NIH, Bethesda, MD 20892, USA.
Yoshiaki NishimuraLaboratory of Molecular Microbiology, NIAID, NIH, Bethesda, MD 20892, USA.
John R MascolaHumoral Immunology Section, Vaccine Research Center, NIAID, NIH, Bethesda, MD 20892, USA.
Malcolm A MartinLaboratory of Molecular Microbiology, NIAID, NIH, Bethesda, MD 20892, USA.
Richard A KoupImmunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD 20892, USA. rkoup@mail.nih.gov.
National Institutes of Health · USColumbia University · USFrederick National Laboratory for Cancer Research · US

Funding

Tfh and B cells in HIV/SIV pathogenesis and vaccinationZIAAI005015 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI KOUP, RICHARD A · 2009 to 2025
$24.1M
The Biology of HIV InfectionsZIAAI001213 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI MARTIN, MALCOLM · 2016 to 2025
$23.7M
HIV/SIV Replication In VivoZIAAI005014 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI KOUP, RICHARD A · 2009 to 2025
$22.7M
Host Genomic Factors in Infectious Disease Susceptibility ZIAAI005066 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DOUEK, DANIEL CESAR · 2009 to 2025
$17.9M
T Cell Immune Responses To HIV And Other PathogensZIAAI005033 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DOUEK, DANIEL CESAR · 2009 to 2025
$11.4M
Primate Lentivirus PathogenesisZIAAI000998 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI MARTIN, MALCOLM · 2009 to 2015
$11.3M
Intramural NIH HHSPHS HHS HHSN261200800001E
6 · The paper itself

Abstract

Broadly neutralizing antibodies (bNAbs) protect against HIV-1 infection, yet how they are generated during chronic infection remains unclear. It is known that T follicular helper (TFH) cells are needed to promote affinity maturation of B cells during an immune response; however, the role of TFH during HIV-1 infection is undefined within lymph node germinal centers (GCs). We use nonhuman primates to investigate the relationship in the early stage of chronic SHIVAD8 (simian-human immunodeficiency virus AD8) infection between envelope (Env)-specific TFH cells, Env-specific B cells, virus, and the generation of bNAbs during later infection. We found that both the frequency and quality of Env-specific TFH cells were associated with an expansion of Env-specific immunoglobulin G-positive GC B cells and broader neutralization across HIV clades. We also found a correlation between breadth of neutralization and the degree of somatic hypermutation in Env-specific memory B cells. Finally, we observed high viral loads and greater diversity of Env sequences in rhesus macaques that developed cross-reactive neutralization as compared to those that did not. These studies highlight the importance of boosting high-quality TFH populations as part of a robust vaccine regimen aimed at eliciting bNabs.

Indexed as

Antibodies, NeutralizingSimian Immunodeficiency VirusAnimalsHIV-1Macaca mulattaMolecular Sequence DataPrimatesSimian Acquired Immunodeficiency SyndromeT-Lymphocytes, Helper-InducerAntibodies, Neutralizing

Identifiers

PMID26223303
OpenAlexW2162604485

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.